Pliant Therapeutics, Inc. (FRA:9PT)

Market Cap	47.75M -50.1%
Revenue (ttm)	n/a
Net Income	-80.78M
EPS	-1.34
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	893
Open	0.7475
Previous Close	0.7710
Day's Range	0.7475 - 0.7550
52-Week Range	0.7470 - 1.2000
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 49
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9PT

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error